Well now that the value chain in the Biotech ASX is now being tested in terms of speculation V actual achievments/potenial and risk off conditions, note that other anti inflamatory stocks like CYP and PAR, are flailing. And that MSB is now leading them.
IMHO, CYP nor PAR do not have anywhere near the depth of value MSB has.
My price of $4.85 reflects more risk off in the Biotech sector (read MSB has less risk), advancement in ARDS, and subsequent consenus that Rynocil, will be appoved by the FDA. MSB have a maturity that will provide momentum in this process.
There will be a flight to quality.
Well now that the value chain in the Biotech ASX is now being...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |